Sanofi’s Hudson Nears Goal of Splitting Off Consumer Health Unit
- The drugmaker is working to focus on cutting-edge therapies
- Sanofi joins the likes of GSK which spun off Haleon in 2022
This article is for subscribers only.
Sanofi is nearing the sale of its consumer health business to Clayton Dubilier & Rice, a year after Chief Executive Officer Paul Hudson announced plans to split off the division to concentrate on developing innovative medicines.
The French drugmaker is in talks to sell a 50% controlling stake in the unit to the US buyout firm, Sanofi said Friday, confirming a Bloomberg News report that it was close to an agreement with CD&R. Financial terms weren’t disclosed, but people familiar with the matter said earlier that the deal would value the unit at about €15 billion ($16.4 billion).